About Piramal Pharma
Piramal Pharma is a company based in Mumbai (India) founded in 1996. The company has 8,560 employees as of March 31, 2024. Piramal Pharma offers products and services including Pharma Solutions, Critical Care, and Consumer Healthcare. Piramal Pharma operates in a competitive market with competitors including Merck, AbbVie, Lilly, Roche and Novo Nordisk, among others.
- Headquarter Mumbai, India
- Employees 8560 as on 31 Mar, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Piramal Pharma Limited
-
Annual Revenue
$1.07 B (USD)11.93as on Mar 31, 2025
-
Net Profit
$10.67 M (USD)411.39as on Mar 31, 2025
-
EBITDA
$177.56 M (USD)20.37as on Mar 31, 2025
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
8560
as on Mar 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Piramal Pharma
Piramal Pharma is a publicly listed company on the NSE with ticker symbol PPLPHARMA in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Piramal Pharma
Piramal Pharma offers a comprehensive portfolio of products and services, including Pharma Solutions, Critical Care, and Consumer Healthcare.
Provides end-to-end drug development and manufacturing services
Offers inhaled anesthetics and hospital products globally
Sells over-the-counter health items like Littles and Lacto Calamine
People of Piramal Pharma
Unlock access to complete
Unlock access to complete
Funding Insights of Piramal Pharma
Investments & Acquisitions by Piramal Pharma
Investment portfolio details for Piramal Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Piramal Pharma
Detailed financials for Piramal Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Piramal Pharma Comparisons
Peer comparison for Piramal Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Piramal Pharma
Piramal Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, AbbVie, Lilly, Roche and Novo Nordisk, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Pharmaceuticals and diagnostics kits are developed for various diseases.
|
|
| Locked | Locked | Locked |
Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
Detailed competitors of Piramal Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Piramal Pharma
Complete news archive for Piramal Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Piramal Pharma
Piramal Pharma was founded in 1996 and raised its 1st funding round 24 years after it was founded.
Piramal Pharma is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
Peter De Young is the current CEO of Piramal Pharma.
As of Mar 31, 2024, the latest employee count at Piramal Pharma is 8,560.
Annual revenue of Piramal Pharma is $1.07B as on Mar 31, 2025.
Piramal Pharma was established in 1996 in Mumbai, India, as a global pharmaceutical entity. Operations span multiple facilities where a diverse range of products and services is manufactured and supplied. Focus is placed on differentiated pharmaceutical offerings within the healthcare sector. End-to-end capabilities support innovation in drug development and production across international markets.
Piramal Pharma's top competitors include Merck, Roivant Sciences and Amgen.
Piramal Pharma offers Pharma Solutions, Critical Care, and Consumer Healthcare.
Yes, Piramal Pharma is publicly traded on NSE under the ticker symbol PPLPHARMA.
The ticker symbol of Piramal Pharma is PPLPHARMA on NSE.